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Abstract
To date, there is no shared consensus on a definition of a complex abdominal wall in elective surgery and in the emergency, on 
indications, technical details, complications, and follow-up. The purpose of the conference was to lay the foundations for a homo-
geneous approach to the complex abdominal wall with the primary intent being to attain the following objectives: (1) to develop 
evidence-based recommendations to define “complex abdominal wall”; (2) indications in emergency and in elective cases; (3) 
management of “complex abdominal wall”; (4) techniques for temporary abdominal closure. The decompressive laparostomy 
should be considered in a case of abdominal compartment syndrome in patients with critical conditions or after the failure of a 
medical treatment or less invasive methods. In the second one, beyond different mechanism, patients with surgical emergency 
diseases might reach the same pathophysiological end point of trauma patients where a preventive “open abdomen” might be 
indicated (a temporary abdominal closure: in the case of a non-infected field, the Wittmann patch and the NPWT had the best 
outcome followed by meshes; in the case of an infected field, NPWT techniques seem to be the preferred). The second priority 
is to create optimal both general as local conditions for healing: the right antimicrobial management, feeding—preferably by the 
enteral route—and managing correctly the open abdomen wall. The use of a mesh appears to be—if and when possible—the gold 
standard. There is a lot of enthusiasm about biological meshes. But the actual evidence supports their use only in contaminated 
or potentially contaminated fields but above all, to reduce the higher rate of recurrences, the wall anatomy and function should be 
restored in the midline, with or without component separation technique. On the other site has not to be neglected that the use of 
monofilament and macroporous non-absorbable meshes, in extraperitoneal position, in the setting of the complex abdomen with 
contamination, seems to have a cost effective role too. The idea of this consensus conference was mainly to try to bring order in 
the so copious, but not always so “evident” literature utilizing and exchanging the expertise of different specialists.
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Introduction
The management of complex abdominal problems with the 
“open abdomen” (OA) technique has become a routine pro-
cedure in surgery. The number of cases treated with an OA 
has increased dramatically because of the popularization of 
damage control for life-threatening conditions, recognition, 
and treatment of intra-abdominal hypertension and abdomi-
nal compartment syndrome and new evidence regarding the 
management of severe intra-abdominal sepsis [1].
Although OA has saved numerous lives and has 
addressed many problems related to the primary pathol-
ogy, this technique is also associated with serious com-
plications. New knowledge about the pathophysiology 
of the OA and the development of new technologies for 
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temporary abdominal wall closure has helped improve the 
management and outcomes of these patients [2].
To date, there is no shared consensus on a definition 
of a complex abdominal wall in elective surgery and in 
the emergency, on indications, technical details, complica-
tions, and follow-up [3]. These thoughts and the desire to 
establish recommendations based on clinical evidence led 
to the organization of the Italian Consensus Conference, 
held in Genoa (Italy) on 24 and 25 June 2015.
The purpose of the Conference was to lay the founda-
tions for a homogeneous approach to the complex abdomi-
nal wall with the primary intent being to attain the follow-
ing objectives:
1. To develop evidence-based recommendations to define 
“complex abdominal wall”;
2. Indications for open abdomen in emergency and in elec-
tive cases;
3. Management of “complex abdominal wall”;
4. Surgical details and indication for use techniques for 
temporary abdominal closure;
5. Use of biological and synthetic meshes and follow-up.
Materials and methods
The following parties were involved in the promotion, 
organization and management of the Consensus Confer-
ence (CC): a Promoting Committee (PC), which is com-
posed of several Italian Surgical Societies, a Scientific 
Committee (SC), which designated the team of Experts 
(ES), and the Members of the Jury Panel (JP), which for-
mulated the questions.
Organization of the Consensus Conference
A pre-consensus meeting was held in Rome, on 2 Decem-
ber 2014, in which the SC, the ES, and JP met to properly 
plan the Conference. The organization of the Consensus 
and the roles of all involved parties were presented during 
this meeting.
Issues were exposed and discussed with the ES and JP, 
and the preparatory timing for the delivery of materials by 
the ES was defined.
All of the ES’s reports were submitted to the Scientific 
Secretary by 8 March 2015. The Secretary sent the reports 
(texts and slides) to all members of the Jury prior to the 
CC. In the same cases, the ES requested changes and clari-
fications, which were promptly carried out.
Holding of the Consensus Conference
The Consensus Conference was held in Genoa on 24–25 June 
2015. The ES briefly summarized their reports in a plenary 
session with the Scientific Committee, the JP, and the audi-
ence, and discussion was set up.
Closing session of the Consensus Conference
At the end of the 1st day of the CC, the JP met to draft the pre-
liminary document. Each chapter was discussed and analyzed, 
producing a key statement with a grade of recommendations 
(weak and strong) followed by a commentary to explain the 
rationale and the level of evidence behind the statement. All 
key statements were formulated according to a 10% consen-
sus obtained within the whole group. The following day these 
statements were presented to the audience. Comments from 
the audience were collected and included in the manuscript 
wherever they were deemed to be relevant. A final version of 
the guidelines was prepared a month after the CC and sent to 
all members of the JP for their final approval. The format of 
the Consensus Conference was freely adapted from the stand-
ards of the National Institute of Health (NIH) and the Italian 
Health Institute.
Literature searches and appraisal
The literature research was done by the SC and approved by 
all the members of the Consensus. The Oxford 2011 for grad-
ing clinical studies according to levels of evidence (EL) was 
used. The primary objective of the search was to identify all 
clinical relevant randomized controlled trials (RCT). However, 
reviews, reports, population-based outcomes studies, case 
series, and case reports were also included. Studies containing 
severe methodological flaws were highlighted and downgraded 
as necessary. A systematic review based on a comprehensive 
literature research up to June 2015 was made on Pubmed and 
Cochrane Library. We considered both English and Italian 
language.
We have used as keywords MeSH for example: “abdomi-
nal surgery”, “postoperative complications”, “recurrence”, 
“surgical wall dehiscence”, “open abdomen”, “management, 
laparostomy”, “damage control surgery”, “ventral hernia AND 
incisional hernia”, “mesh, biologic mesh, contaminated field, 
cross-linked, non-cross-linked”, “congenital abdominal wall 
defect AND biological prosthesis”; “abdominal wall closure 
AND pediatric transplant”.
Results
The Jury undertook every reasonable endeavor to answer 
the following questions:
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1A. Definition of “Complex abdomen” in the emergency:
An abdomen may be defined as complex when there is a 
high-risk of (1) compartment syndrome, (2) suture dehis-
cence, (3) early re-do laparotomy/second look (STRONG 
RECOMMENDATION).
These clinical situations are related to patient’s risk fac-
tors, disease risk factors and type of surgery. Abdominal 
wall closure represents a serious problem to solve by the 
surgeon in a complex surgical situation such as laparot-
omies in critical patients and in emergency surgery for 
difficult trauma, large ventral hernia, peritonitis or bowel 
occlusion. One of the main questions is either if to close 
the muscular fascia or not and which type of surgical clo-
sure is better to minimize the postoperative complications. 
Despite this problem’s frequency there’s still not a general 
consensus regarding the criteria to defined “complex” an 
abdominal wall closure [4, 5] (EL 3).
Several different multifactor scoring systems predictive 
of abdominal wall suture complications have been pro-
posed in literature such as the VAMC score and the Rot-
terdam score [5] (EL 3). According to them age > 70 years 
old, obesity, cigarettes, steroid use or cytostatic, diabetes, 
malnutrition, ASA III and IV, vascular disease, constipa-
tion, ascites, BPCO, hospital length of stay, sepsis and pre-
vious laparotomies [4–6] (EL 5) were indicated as patients 
risk factors. Whereas disease and surgical risk factor con-
nected with abdominal wall suture complications included 
abdominal trauma, ruptured abdominal aortic aneurysm, 
retroperitoneal hemorrhage, pancreatitis, peritonitis, bowel 
occlusion surgery with bowel resection or suture, wound 
infection, presence of enterocutaneous fistula, large sized 
abdominal wall > 10 cm in width, multiple ventral defects, 
loss of domain > 20%, synthetic mesh infection, necrotiz-
ing fasciitis, surgical procedure with wound class III (con-
taminated) or IV (dirty), closure of a laparostomy, head 
trauma with head hypertension, surgical abdominal closure 
with component separation or use of synthetic or biologi-
cal mesh [1, 4–9] (EL 5).
1B. Definition of “Complex abdomen” in elective surgery.
When there are one or more of these conditions: (1) 
loss of domain > 20%; (2) surgical wound class III (Con-
taminated) or IV (Dirty) infection; (3) wound ulcers/
non-healing wound; (4) closure after open abdomen; (5) 
the presence of entero-cutaneous fistula; (6) the presence 
of a previous mesh infection; (7) a recurrent hernia after 
many previous mesh repair attempts; (8) full-thickness 
abdominal wall defects with loss of substance; (9) need 
of intra-peritoneal mesh removal with a wide adhesiolysis 
(especially when determining enterotomy), an abdomen 
may be defined as complex in elective surgery (STRONG 
RECOMMENDATION).
The term ‘‘complex (abdominal wall) hernia” is often 
used by general surgeons to describe hernias that are techni-
cally challenging and time-consuming. Unfortunately, there 
is not a precise consensus on which should be the criteria 
that define the complexity. Moreover, in some cases, the 
complexity is understood only intra-operatively (e.g., bowel 
perforation, e.g., non-predicted adhesions, etc.) [4] (EL 3).
Four categories are the most frequently discussed in the 
literature for the definition of ‘‘complex abdominal wall 
hernia’’.
Defect size, feature, and location
An increased hernia size is considered a risk factor for 
both 30-day readmission due to complications and recur-
rence [10, 11] (EL 4). The width seems to be more informa-
tive than the length of the defect. 10 cm is a useful cut-off 
point for a complex hernia provided there are other compli-
cating factors [12] (EL 5).
Lumbar, lateral, and subcostal locations of hernias are 
considered to be complex because of mesh anchorage dif-
ficulty and risk of recurrence. Additionally, parastomal her-
nias might be considered as complex [13] (EL 4).
When a large proportion of the abdominal contents 
resides permanently in the hernia sac (> 20%), this may be 
considered as a complex hernia [14] (EL 3). Therefore, a CT 
scan is mandatory in determining the complexity abdominal 
wall hernia.
Contamination and soft tissue condition
Contamination and subsequent infection are well known 
to be an important cause of wound dehiscence and re-herni-
ation by disturbing wound healing dynamics [15, 16].
Moreover, as shown in a recent systematic review of Pub-
Med, EMBASE and Cochrane databases evaluating postop-
erative outcomes reported in patients undergoing contami-
nated/infected ventral incisional herniorrhaphy [17] (EL 
1) {hernias with wound classes III (contaminated) and IV 
(dirty/infected) has to be considered complex.
Furthermore, the condition of the soft tissue (such as 
significant loss of skin or presence of a laparostomy cov-
ered with a skin graft, ‘battle- scarred’ abdomen, and loss of 
myofascial tissue due to trauma, tumor resection or debride-
ment) has important consequences for the complexity of sur-
gical treatment.
Patient history and risk factors
A recurrent hernia is considered a risk factor for a new 
recurrence. It is proposed that these patients suffer an under-
lying dysfunction in the wound healing process, leading to 
weakened scar tissue [18] (EL 3). Various other patient-
related variables are included in several classification sys-
tems indicating the following risk factors: age, male gender, 
chronic pulmonary disease, coughing, ascites, jaundice, ane-
mia, emergency surgery, wound infection, obesity, steroid 
use, hypoalbuminemia, hypertension, perioperative shock, 
and type of surgery [5, 19, 20] (EL 3).
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Clinical scenario
Both an emergency hernia repair including bowel resec-
tion and the presence of a previously placed mesh which 
needs to be explanted for any reason were considered by 
various groups to be a complex situation [21, 22] (EL 5) 
due to the necessity, in the latter case, of extensive adhe-
siolysis, longer operating time and increased risk of inad-
vertent enterotomies resulting in dense adhesions, fistulas, 
and infection [23] (EL 2). Besides the clinical scenarios 
described in the classification systems, also the following 
complicating situations that necessitate significant pre- 
and perioperative measures and planning should be added: 
abdominal wall with multiple hernia defects (e.g., a ‘‘bat-
tle-scarred abdomen’’), a non-healing wound, and when no 
primary closure is possible [24] (EL 3). In particular, the 
presence of entero-cutaneous fistulas is known to coincide 
with high morbidity, mortality and fistula and hernia recur-
rence rates [25] (EL 4).
2. Indications to open abdomen in emergency and trauma.
In conditions of Damage Control Surgery, the preventive 
Open Abdomen is indicated in the presence of packing that 
should be removed, massive hemorrhage, severe peritonitis, 
major abdominal and retroperitoneal tissue edema, loss or 
altered tropism of fascia or when it is necessary a second 
look (STRONG RECOMMENDATION).
The therapeutic Open Abdomen both in emergency sur-
gery and in trauma is indicated in cases of compartment 
syndrome in which medical treatment failed (STRONG 
RECOMMENDATION).
Although the therapeutic Open Abdomen is also recom-
mended the cases of intracranial hypertension not respon-
sive to medical therapy: cause the paucity of cases, it is 
not possible to give a greater level of evidence (WEAK 
RECOMMENDATION).
Are the indications to laparostomy the same in emergency 
surgery and trauma surgery?
Although the mechanism is different, some patients with 
nontraumatic, but surgical emergency diseases reach the 
same pathophysiological end-point of trauma patients who 
develop a coagulopathy not mechanical and/or severe state 
of sepsis [26, 27]. For this reason, the indications for use 
of the laparostomy both preventive or decompressive of 
the abdominal cavity are the same both in emergency and 
trauma surgery even if with the lower level of evidence [27, 
28] (EL 3).
When is a preventive laparostomy indicated?
The literature does not clarify definitively the real ben-
efits of preventive laparostomy in patients with high-risk. 
Furthermore, for what concerns the traumatic pathology 
(and others) treated according to the principles of Damage 
Control Surgery, this should not be considered strictly as an 
indication, but as an integral part of the technique.
The preventive laparostomy is indicated in case of Dam-
age Control Surgery [28–32] (EL 2) and in severe abdominal 
hypertension [28–30, 33, 34] (EL 3): in the first case, the 
laparostomy is an integral part of the surgical technique in 
the context of a planned re-operation, in the second one the 
positive effects of abdominal decompression on hemody-
namics and on respiratory and renal functions are obvious, 
but there is no evidence of what is the maximum value of 
intra-abdominal pressure which can be tolerated without risk 
at the end of the first operation; furthermore it is not known 
the cut-off value that makes absolutely indicated a preven-
tive laparostomy.
The preventive laparostomy is also indicated after a 
trauma that results in greater tissue loss or after surgery with 
precarious band conditions. A preventive laparostomy seems 
indicated even in the presence of visceral perforation with 
extensive contamination of the peritoneal cavity or intense 
edema of the bowels and of the retroperitoneum [27, 31–33, 
35–37] (EL 2).
As an outcome, the high morbidity (and mortality) in 
patients undergoing a preventive laparostomy derived from 
the critical condition of the patients rather than from specific 
risk factors of the technique.
When is a decompressive laparostomy indicated?
Decompressive laparostomy should be considered in 
cases of abdominal compartment syndrome in adult patients 
with critical conditions.
In the case of medical treatment or less invasive methods 
failure, such as percutaneous drainage of abdominal abscess, 
surgical decompression is needed; however, the improve-
ment of the organ functions are not strictly related to the 
decline of the intra-abdominal pressure [28–30, 33, 34, 38] 
(EL 2).
Severe intracranial hypertension is a further indication to 
decompressive laparostomy as a help for the medical treat-
ment [39] (EL 3).
3. Temporary Abdominal Closure (TAC) technique.
In the absence of sepsis, the Wittmann patch and Nega-
tive Pressure Wound Therapy (NPWT) abdominal dress-
ing offered the best outcomes. In the presence of sepsis, 
NPWT had the highest delayed primary closure rate and 
lowest mortality, especially when associated with continu-
ous fascial retraction to achieve delayed fascial closure and 
a reduction of the risk of enteroatmospheric fistula (WEAK 
RECOMMENDATION).
Protected non-absorbable and absorbable meshes can be 
used for temporary abdominal closure. Absorbable meshes 
may be left in place at the closure of abdomen, whereas non-
absorbable materials usually need to be removed (WEAK 
RECOMMENDATION).
All TAC systems that do not prevent retraction of the 
fascia should be used if a definitive closure is possible in a 
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short time. They are simple, inexpensive and prevent bowel 
desiccation allowing the conservation of electrolytes and 
thermal effects (STRONG RECOMMENDATION).
The main indications of temporary abdominal closure 
(TAC) technique are prophylactic abdominal decompression, 
planned repeated explorations of the peritoneal cavity and 
the treatment of the abdominal compartment syndrome. Re-
exploration of the abdomen generally occurs after 24–72 h 
[8, 40, 41] (EL 3). A definitive closure can be obtained only 
when the abdominal acute condition and bowel edema are 
resolved and the intra-abdominal pressure remains under 
25–30 mmHg [8, 41, 42] (EL 4). Definitive abdominal 
reconstruction is the ultimate goal but we must consider 
another endpoint in evaluating the TAC techniques, such as 
fistula and abscess rate and associated survival. Any tech-
nique has different features and should be chosen according 
to the specific circumstance [41].
What kind of technique is preferred in the field of not infected 
abdomen?
The Wittmann patch and the negative pressure wound 
therapy (NPWT) had the best outcome followed by meshes. 
Wittmann Patch can be used only as a temporary TAC sys-
tem to prevent lateral fascial retraction and permits adjust-
ments according to the intra-abdominal pressure. It facili-
tates re-operation, but it does not allow effective drainage of 
intra-abdominal infectious fluid. Furthermore, it is related 
to an increased rate of enterocutaneous fistula. In addition, 
there is a concern that the sutures on the fascia might cause 
ischemic damage to the edges, making the definitive closure 
more difficult [8, 30, 42–45] (EL 3).
What kind of technique is preferred in the field of the infected 
abdomen?
In the case of the infected/contaminated abdomen, NPWT 
techniques play an important role: removal of peritoneal 
fluid, inflammatory mediators reduces the concentration 
of cytokines in the bloodstream and approximation of the 
fascial edges [46] (EL 1) [47] (EL 3). There are different 
types of NPWT techniques: Barker, Vacuum Assisted Clo-
sure (VAC) abdominal dressing system and ABThera sys-
tem. ABThera seems to achieve a better performance con-
cerning: survival, the rate of enterocutaneous fistulas and 
removing of peritoneal fluids [48] (EL 4–5). Furthermore, 
ABThera system, compared to the others, demonstrated to 
produce a smaller negative pressure on the bowel loops, with 
a lower enterocutaneous fistula rate fluids [48] (EL 5). Atten-
tion has to be paid to incomplete hemostasis and high-risk 
anastomosis fluids [48] (EL 5). Dressing changes are per-
formed every 1–3 days or even more frequently when there 
is an abdominal contamination or infection. Moreover, the 
combination of ABThera and abdominal re-approximation 
anchor system (ABRA) has been demonstrated to be ideal in 
managing patients who may not achieve primary fascial clo-
sure with ABThera alone. In fact, ABRA helps to overcome 
ABThera’s system limited ability to stabilize the fascia in 
some patients [8, 45, 48–52] (EL 4–5).
When can be used a technique that does not prevent fascial 
retraction?
Bogota bag, steridrape, sylastic sheet, silicon sheeting, 
skin approximation, and zipper might be valuable in cases 
with damage control for intra-abdominal bleeding in which 
definitive closure is anticipated within the next 2 or 3 days 
[9, 53, 54] (EL 3). No fluid removal is possible and should 
not be left in place more than 3–14 days [1, 53, 54] (EL 3).
When can be used meshes in TAC?
Absorbable meshes are always related to the development 
of a large ventral hernia, needing an additional operation. 
Their function is to prevent fascial retraction while facilitat-
ing re-operation and a stepwise approximation of the fascial 
edges. It does not allow peritoneal fluids remove so it should 
not be used in case of sepsis. Meshes combined with nega-
tive pressure therapy (NPT) technique, in some studies, have 
been reported to improve the primary fascial closure rates. 
They carry a high incidence of enterocutaneous fistula. In a 
case of contamination, it should be used a biologic mesh as 
a temporary or definitive solution. Despite their cost and low 
availability, biologic material seems to perform better in a 
condition of infection as it clear bacteria and revascularized. 
Further studies should be done to assess the role of biologic 
meshes in TAC [29, 55–58] (EL 4–5).
4. Decision-making in the management of open abdomen.
It’s recommended to close the abdomen as quickly 
as possible. It is suggested within 9  days (STRONG 
RECOMMENDATION).
It’s recommended to revise TAC system every 24–72 h 
and to explore the abdomen only if it’s necessary. A restric-
tive fluid resuscitation and a strict control of the infections 
is suggested (WEAK RECOMMENDATION).
Trauma surgeons have gained a huge amount of experi-
ence with multiple techniques used to achieve abdominal 
closure of the open abdomen, but questions still remain: 
How long can the abdomen remain open? When does the 
risk of complications begin to increase? Is there a specific 
technique that is better than the rest for closing the open 
abdomen? At what point should all attempts at delayed fas-
cial closure be abandoned and a planned ventral hernia per-
formed [59]?
The optimal timing for abdominal closure has not been 
determined and varies widely between different series. 
Miller et al. demonstrated that DAFC (delayed abdominal 
closure) before 8 days was associated with fewer complica-
tions: 12% in those closed before 8 days and 52% in that 
closed after 8 days. Lambertz et al. showed a similar result 
and underlined that the presence of peritonitis is not a nega-
tive prognostic marker concerning fascial closure, while the 
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presence of pancreatitis seems to influence the rates of fas-
cial closure negatively [60–64] (EL 4).
In 2009, the Open Abdomen Advisory Panel [65] was 
formed to identify the core principles of open abdomen man-
agement. They emphasized that throughout the management 
of a patient with an open abdomen, “a central goal is the clo-
sure of the abdominal defect as quickly as possible without 
precipitating abdominal compartment syndrome”, defining 
it as the most effective way to reduce the complications asso-
ciated with the OA. A combination of three strategies such 
as (1) avoidance of excessive fluid resuscitation, (2) use of 
effective NPT dressings for temporary abdominal wall clo-
sure and (3) use of biological materials in appropriate cases 
for definitive fascial closure [66] (EL 4) has been indicated 
to achieve this purpose.
The timing of the re-exploration of an abdomen gener-
ally occurs after 24–72 h. At this time the initial adhesions 
between the viscera and the peritoneal surface are easily 
separable and the access to any space with no-traumatic 
dissection is quite feasible. In this stage, it is possible to 
perform total exploration of the abdominal cavity. After, the 
intra-abdominal structures begin to adhere to each other, 
cemented by massive adhesions, vascularized and difficult 
to separate (frozen abdomen). A definitive closure can be 
obtained only when the abdominal pathology and bowel 
edema are resolved and the intrabdominal pressure remains 
under 25–30 mmHg [8, 41] (EL 4).
Greater number of serial abdominal explorations, the 
fluid volume overload, abdominal abscess and enterocutane-
ous fistulae were negatively associated with primary fascial 
closure [67] (EL 4).
In the setting of ongoing intra-abdominal infection or the 
formation of an enterocutaneous fistula abdominal fascial 
closure is often not possible. The fascial closure may not 
be possible because of ongoing visceral edema with loss of 
abdominal domain or from loss of fascia from infection. At 
this point, a fascial bridge closure of the resulting abdominal 
fascial defect may be considered. The surgeon is limited in 
the available surgical options: (1) bridge repair of the fascial 
defect using a mesh to create a bridge closure, (2) perform-
ing an acute abdominal wall reconstruction using most com-
monly a version of component separation, or (3) a planned 
ventral hernia using adsorbable mesh (vicryl or dexon mesh 
and skin graft or skin flaps) [59] (EL 4–3).
5–6. When a biologic graft may or must be used in a com-
plex abdominal wall repair?
The biological prosthesis should be implanted only 
in clinical cases where is present a contaminated or 
potentially contaminated surgical field (STRONG 
RECOMMENDATION).
The use of not cross-linked material should be associated 
with abdominal wall midline restoration, with or without 
component separation, due to a higher recurrence rate in 
the bridge repair without midline restoration (WEAK 
RECOMMENDATION).
The cross-linked material could be used in case of midline 
restoration. It should be used in case of bridging thanks to 
a higher tensile strength (WEAK RECOMMENDATION).
Waiting for stronger scientific evidence, the surgeon 
should orientate their choice case by case, evaluating the 
main target: resistance to tissues tension or prevention of 
mesh infections.
Despite advances in surgical technique and prosthetic 
technologies, repair of complex anterior abdominal wall 
defects, particularly when bacterial contamination is pre-
sent or the risk of infection is high, remains a complex and 
challenging surgical undertaking. Although permanent pros-
thetic mesh is considered the gold standard for minimiz-
ing hernia recurrence, their non-absorbable characteristics 
may cause potential problems, resulting in erosion into the 
abdominal viscera, bowel fistulae, and chronic pain, which 
can lead to more complex and costly surgery. Moreover, 
placement of synthetic mesh is sometimes imprudent, espe-
cially in high-risk contaminated wounds. Consequently, 
within the past decade, several bioprosthetic materials have 
been developed to support tissue reconstruction while mini-
mizing the potential complications that come from foreign 
material reactions of synthetic mesh and their potential to 
act as a site for infection. As all mesh prostheses, the pur-
pose of the biologic graft is to assist a tension-free closure 
of incisional wounds. It is also promoted as being able to 
integrate better than synthetic mesh into the healing matrix 
and resist to infection, essentially expanding its potential 
use in areas where the synthetic mesh is otherwise contrain-
dicated [68] (EL 3). In accordance with the guidance set 
by the ventral\hernia working group, biological prosthesis 
should be implanted only in clinical cases where is present 
a contaminated or potentially contaminated surgical field 
as previous site infection, the presence of a stoma, acciden-
tal or programmed violation of the gastro-intestinal tract or 
a history of mesh infection or removing an infected mesh 
[69] (EL 3). Therefore, the attention on literature has been 
specifically focused on the biologic mesh in ventral hernia 
repair under contaminated conditions [70] (EL 2). To date, 
there have been four clinical reviews which concluded that 
biologic mesh should be incorporated in every surgeon’s 
armamentarium, especially in the setting of contaminated 
fields, but a closer look at the primary studies reported in 
these reviews indicates that such positive conclusions are not 
at all warranted, for several reasons. The primary literature 
that served as the basis for this conclusion consisted entirely 
of case series that varied widely in terms of sample size, 
mesh material used, how the mesh material was placed, and 
how the results were reported [68] (EL 3), [69] (EL 2), [71] 
(EL 3), [72] (EL 4) and another systematic review included 
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biologic meshes as part of a larger discussion on available 
prosthetics for ventral hernia repair [73] (EL 3). This incon-
sistency makes it difficult, if not impossible to compare stud-
ies and drawing conclusions from them premature. However, 
biologic grafts offer the potential to perform single-staged 
repairs of contaminated or potentially contaminated ventral 
hernias with a real improvement in terms of social, eco-
nomic and emotional costs if compared to lead towards a 
planned hernia, as in the past [73, 74] (EL 2–3). But, despite 
the rapid acceptance of these different materials into the sur-
gical community, there are still many unanswered questions 
about biologics as their mechanism of action, ideal source 
material, the effect of post-harvesting processing methods 
and most appropriate placement techniques [75, 76] (EL 2).
Theoretically, they provide a scaffold for native cel-
lular regeneration and neovascularization. Several animal 
experiments and case reports of re-exploration and biopsy 
evaluation have confirmed neovascularization and fibroblast 
deposition, but in not contaminated fields [77] (EL 2). The 
ability to rapidly vascularize, in a potentially infected field, 
might prevent bacterial colonization, degradation and graft 
failure. Recent animal models have confirmed the varied 
ability of different biologic grafts to clear bacterial con-
tamination [78] (EL 3). Apart from the animal and tissue of 
origin, biological meshes differ in the de-cellularization and 
sterilization processes, material size and thickness, as well 
as the presence of cross-linking. Cross-links are bonds that 
link the collagen chains together and are present to a degree 
in all natural collagens. Additional cross-linking resists the 
degradation of collagen scaffolds by either host or bacte-
rial collagenases and is claimed to enhance mesh durabil-
ity. Moreover, in human beings, the biological response 
might be influenced by post-harvesting processing which 
modified the characteristic of the graft, as in the case of a 
cross-linking process which promotes a resistance to matrix 
metalloproteinase and stabilizes the structure of collagen, 
that lead to a long-lasting surgical implant [79] (EL 2). The 
theoretical advantages of cross-linked meshes may result in 
lower hernia recurrence rates, especially in complex hernia 
repair and contaminated/infected fields but the methodologic 
quality of the studies about this topic was generally poor, 
common reporting weaknesses included the following: lack 
of reporting wound classification, lack of a control group, 
failure to provide information on surgical technique and out-
comes, failure to report which patients were lost to follow-up 
evaluation, and failure to provide biological mesh-specific 
information on hernia recurrence. Nevertheless, histologi-
cally, non-cross-linked materials exhibited greater cellular 
infiltration, extracellular matrix (ECM) deposition and neo-
vascularization compared to cross-linked [80–83]. These 
results may explain the report of a relatively higher infection 
and explantation rates observed in cross-linked compared to 
non-cross-linked grafts [84] (EL 2). In contrast to these data 
a recent systematic review comparing cross linked and not 
cross-linked porcine meshes showed that more mesh infec-
tions occurred in the latter group. Findings appear to be con-
troversial and at the light of these results, the surgeon has 
to face the choice of a graft to implant, balancing between 
mesh strength and durability or optimal tissue integration 
[76] (EL 2). Furthermore, the effectiveness of the biologi-
cal mesh has subsequently been questioned in the case of 
surely infected fields, in which the incidence of surgical site 
occurrence (SSO) is similar to synthetic material use [85] 
(EL 3). Particularly the most frequently described major 
complication in biologic graft abdominal wall repair was 
recurrence ranging from 0 to 100%, with an overall weighted 
recurrence rate of 15.2% [86] (EL 3). These results could be 
widely influenced by appropriate graft placement techniques 
[87] (EL 2) and as showed, bridge repair without a midline 
restoration is affected by highest recurrences rates as 46.5% 
of cases, especially among non-cross-linked grafts [84] (EL 
2). The level of contamination in the surgical site may also 
influence the recurrence rate by higher level of explanted 
meshes especially among cross-linked graft [88] (EL 2). The 
component separation, described for the first time by Ram-
irez [89], may address the problem, restoring anatomy and 
physiological function of the abdominal wall and by giving 
much more strength, through mesh interposition [90] (EL 1). 
As confirmed in a prospective multicenter randomized trial 
(RICH Study) [91] (EL 1) on a total of 80 patients with ven-
tral incisional hernia repair in contaminated surgical field, 
the midline closure, with or without component separation 
and associated to a dermal porcine non-cross-linked graft, 
shows at 24 months after operation 25% recurrence rate in 
patients, with defects ranging from 203 to 220 ± 150 cm2, 
so close to the outcome following synthetic mesh repair in 
not contaminated surgical fields [92] (EL 1). Moreover, a 
proposal for a decisional model about the biological mesh 
use came from “Italian Biological Prosthesis Work-Group 
(IBPWG)”. According to this study, using a scoring model 
that combines infection grade with tissue lost grade, it would 
be is possible to achieve information about the best biologi-
cal mesh choice [93] (EL 3).
From the limited studies that are present in the literature, 
there appears to be an acceptable overall recurrence rate of 
20% and an infection rate of 24% [94] (EL 1). However, the 
evidence in the literature suggests that the total number of 
reported studies using biological mesh in infected fields for 
abdominal wall reconstruction in humans is low and most 
studies are of poor methodology.
7. When a synthetic mesh may or must be used in a complex 
abdominal wall repair?
All complex ventral hernia repairs (VHR) should be 
reinforced with prosthetic repair materials, but there is a 
significant increase in the risk of postoperative occurrences 
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using mesh in clean-contaminated and contaminated cases 
compared to clean cases (WEAK RECOMMENDATION).
The use of monofilament and macroporous non-absorba-
ble meshes, in extraperitoneal position, in the setting of the 
complex abdomen with contamination seems a cost effective 
approach (WEAK RECOMMENDATION).
Fascial traction technique with synthetic meshes com-
bined to NPWT therapy in temporary abdominal closure 
shows a lower rate of enteroatmospheric fistula respect the 
use of mesh alone (synthetic and biologic) in inlay position 
(WEAK RECOMMENDATION).
Further clinical trials are needed to characterize the use of 
new synthetic bioabsorbable 3D and 2D meshes in complex 
abdominal wall repair.
All complex ventral hernia repairs (VHR) should be rein-
forced with prosthetic repair materials [95, 96] (EL 2), [97] 
(EL 3), but there is a significant increase in risk of postopera-
tive occurrences using synthetic mesh in clean-contaminated 
and contaminated cases relative to clean cases [69] (EL 3), 
[98, 99] (EL 2), [100] (EL 3). The use of monofilament and 
macroporous non-absorbable meshes in the setting of a com-
plex hernia and/or contamination seems, in extraperitoneal 
position, a cost-effective approach than bioprosthetic mesh 
[101] (EL 2), [102–109] (EL 3). Fascial traction technique 
with synthetic meshes combined with VAC therapy in tem-
porary abdominal closure shows a lower rate of enteroatmos-
pheric fistula respect the use of mesh alone (synthetic and 
biologic) in inlay position [45] (EL 2), [110] (EL 5). Early 
results of a multicentric and prospective study on VHR using 
synthetic bioabsorbable 3D mesh demonstrate that this mesh 
in contaminated fields, in intra and extraperitoneal position, 
shows the ability to resist infection and remodel by the time 
with good results in terms of infection and recurrences rate 
[111] (EL 4), [112–114], (EL 3). In literature are present 
only pre-clinical studies and case reports, consequently, 
further clinical studies are needed to better characterize the 
use of new synthetic bioabsorbable 2D meshes in complex 
abdominal ventral hernia repair [115–118] (EL 4).
8. Biological prosthesis implant in pediatric and neonatal 
surgery.
The use of biological prosthesis is safe and feasible in 
pediatric abdominal wall closure. The use of the biologi-
cal prosthesis in a contaminated surgical field improves the 
surgical outcome without the need of prosthesis removal in 
case of infection. The use of biological prosthesis allows the 
abdominal wall closure after pediatric abdominal transplan-
tation. The use of biological prosthesis allows the abdomi-
nal wall closure in patients with congenital abdominal wall 
defects (WEAK RECOMMENDATION).
Repair of congenital abdominal wall defects, diaphrag-
matic hernia with abdominal muscle aplasia, and abdominal 
wall closure of pediatric transplant recipient with donor size 
discrepancy have seen the use of prosthetic patches of non-
absorbable materials which represented a valid solution but 
can be a source of infection and complications. Biologic 
grafts have been introduced as an alternative to synthetic 
mesh.
No systematic reviews were found for the pediatric 
population.
There are few and limited studies published on the appli-
cation of biologic mesh for pediatric abdominal wall closure. 
They are very heterogeneous, mainly because they describe 
different kinds of graft, different patient characteristics and 
pathologies, different surgical indications and techniques. 
Then a comparison of the data in the literature is really 
difficult.
The two more recent reviews conclude that biologic grafts 
perform similarly to synthetic mesh for incisional hernia 
repair and they are associated with a high salvage rate when 
infected [86, 88] (EL 3).
Other two reviews suggest that cross-linked mesh has the 
best clinical outcomes in contaminated or infected fields 
[119, 120] (EL 3).
The last review affirms that allograft acellular dermal 
matrix have a higher recurrence rate as compared with xeno-
graft products [121] (EL 3).
Regarding the use of the biological prosthesis in congeni-
tal abdominal wall defect, only one study was identified. It 
is about repair of a congenital diaphragmatic hernia. 15/118 
patients were treated with an abdominal patch (eight with 
diaphragmatic patch, seven with primary diaphragmatic 
repair). In this group, the mortality rate was significantly 
higher. A similar trend was also observed in diaphragmatic 
patch versus non-patch group [122] (EL 4).
Other studies suggest that biological mesh (Permacol, 
Surgisis, Strattice) allow complete abdominal closure after 
transplant (liver, intestine, kidney, multi-visceral) in children 
with donor size discrepancy. Biological prosthesis seems 
to have long-term durability with no incisional hernia on 
short and medium-term follow-up [123–127] (EL 4). The 
three articles selected assert that Permacol was effective for 
the reconstruction of the abdominal wall defect in particular 
cases: multi-trauma, conjoined twin, and in assisting abdom-
inal wall closure of pediatric renal transplant recipient [124, 
128, 129] (EL 4).
In pediatric patients affected by giant omphalocele, the 
biologic mesh was applied as a primary abdominal fascia 
substitute with good results, no fascial dehiscence or infec-
tion [130–132] (EL 4). Surgisis was implanted for abdominal 
wall defects due to different pathologies: omphalocele, gas-
troschisis, ventral hernia after diaphragmatic hernia repair, 
omphalopagus conjoined twins and liver transplantation. 
In these case series, some complications occurred: wound 
infection, seroma formation, and recurrence. None required 
patch removal [125, 126, 133–135] (EL 4).
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The low level of evidence of the case studies presented, 
the lack of randomized studies, the lack of age-related pedi-
atric review only allow us to suppose that there is a good 
outcome with the use of biological prostheses. We cannot 
then formulate which are the real clinical indications for the 
use of a biological prosthesis rather than a synthetic one. 
This is the same conclusion shared by the latest reviews 
about adult population. Randomized controlled trials are 
necessary to determine the right application of biologic 
prosthesis.
9. Which follow-up in the biological mesh?
Patients with biological prosthetic repair of the complex 
abdomen should undergo careful follow-up with outpatient 
clinical examination every 12 months after surgery up to 
5 years of follow-up. Suspected recurrent hernia or wound 
complaints should be evaluated by abdominal CT or MRI 
study (STRONG RECOMMENDATION).
Three biological grafts were found almost exclusively 
in the Literature in ventral incisional hernia repair (VIHR) 
in critical conditions and were included in this analysis: 
 Alloderm®,  Permacol®,  Strattice® and  Surgisis®.
A recent review [74] (EL 3) on studies with at least Lev 4 
evidence and at least 40 patients undergoing VIHR came up 
with 461 total patients. Contamination (Grade 4, according 
to the grading system of ventral incisional hernia introduced 
in 2010) or clean/contamination (grade 3) was present in 
32–100% of the cases, depending on the study and the type 
of prosthetics used. The mean follow-up for  Alloderm®, 
 Strattice® and  Surgisis® patients was 25.9, 24 and 
20.5 months, respectively and recurrence rates 30.1, 28 and 
18.1%. With an average follow-up of only 25 months in the 
whole cohort of patients, it was not easy to draw conclusions 
regarding long-term results. Such short follow-up is con-
cerning, considering that most recurrences could take place 
outside the 2-year follow-up window. We don’t know if there 
is any ‘plateau’—at some point—in the recurrence rate. In 
Itani’s paper [91] (EL 4), nearly half of the infection-related 
complications (including abscesses and sinuses) described 
after using  Strattice® in dirty, contaminated and clear/con-
taminated cases were late-occurring. Hernia recurrences 
were 19% by month 12 and 28% by month 24. Therefore, 
both the temporal relationship between repair and recurrence 
and repair and occurrence of complications, which is differ-
ent for each mesh and is missing in the literature, would be 
of great interest. This could be available only with a strict 
follow-up and a meticulous retrieve of data from outpatient 
clinical examination. A ‘freedom from recurrence’ point 
could be defined only after scrutiny of long-term follow-
up of prospective studies and also a precise definition of 
postoperative complications might require prolonged follow-
up. As reported in Jin study on  Alloderm® [136] (EL 4) 
their median patients’ follow-up was 21.4 months (range 
15–36 months) and the mean time to hernia recurrence was 
1 year, although recurrences occurred at 31 months, indicat-
ing the importance of continued follow-up.
An interesting review [137] (EL 3) focused on the claimed 
superiority of biological over synthetic mesh in VIHR under 
contaminated conditions. Four clinical reviews and one sys-
tematic review were identified with a total of 25 primary 
articles: only ten had a mean follow-up time longer than 
12 months and yet they all concluded supporting the contin-
ued use of biological meshes in contaminated fields. To note, 
quite a few studies reported only perioperative outcomes 
and in studies, with longer follow-up a range of follow-up 
was given but the total number of patients available for fol-
low-up was missing. In this review the follow-up ranges for 
Alloderm, Surgisis and Permacol were, respectively: 6–22, 
14–29 and 11–18 months. The short-term picture provided 
by most articles on biological mesh use in VIHR makes a 
comparison with synthetic mesh quite complicated, because 
of different follow-up times. Recurrence occurring after the 
short-term period of follow-up might be underestimated. In 
this light, the early termination of the LAPSIS trial (rand-
omized study of  Surgisis® vs. classical synthetic mesh for 
clean primary ventral and incisional hernia) should be kept 
in mind: the higher preliminary recurrence rate in the bio-
logical mesh group compared with the synthetic one was 
one of the key factors for the premature interruption of the 
study [138] (EL 2).
Alloderm® (based on the acellular human dermal matrix) 
represents an example of the importance of long-term fol-
low-up to better define the characteristics and the tempo-
ral behavior of different meshes. It is the biological mesh 
with longer follow-up available in the Literature. It has been 
reported to “relax” over time: high elastin/collagen ratio, 
insufficient pre-stretching, lack of additional cross-linking, 
and thin and vulnerable border regions because of the der-
matome harvest from human cadavers might be responsible 
for bulging and eventration [88] (EL 2). Actually, laxity does 
not necessarily affect patient’s functionality and is not clear, 
yet, if and how it affects patients’ life. So, longer follow-up 
studies on quality of life data might help to solve this issue. 
The idea that chemical cross-linking affects and significantly 
reduces the overall stretch of the elastin fiber found in all 
dermis-based grafts is a hypothesis and as such needs to 
be tested in the long-term follow-up to confirm better pre-
liminary short-term results of cross-linked porcine dermis 
derived meshes compared to  Alloderm®. On the other side, 
if it is true—as suggested by recent reports [139–141] (EL 
3–4) that long-term graft stretching may occur even after 
pre-stretching of the graft, then the diastasis and/or hernia 
recurrence rates can be assumed to increase over time as the 
graft continues to stretch and weaken.
The ongoing SIMBIOSE randomized multicenter con-
trolled study, comparing the use of mesh versus standard 
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wound care in infected incisional ventral hernia will have 
preliminary data available after 6 months, but is correctly 
planned to last till a 3-year period of follow-up is reached, 
before correct definitive conclusions on use of biological 
mesh in contaminated field can be drawn [142] (EL 3).
An interesting report [143] (EL 4) was recently published 
on single-staged repair of infected and contaminated abdom-
inal wall defects with biological implants on 128 patients 
(including 102  Strattice® and 16  Alloderm®). With a mean 
follow-up of 21.7 months (range 1–73.8 months) and an 
overall recurrence rate of 31.3%, this paper revealed that her-
nia recurrence truly presented as a broad-spectrum temporal 
event: hernia recurrences occurred as early as 5.6 months 
and as late as 73.4 months after surgery and the mean time 
to recurrence was over 2 years. Authors of this study called 
into question whether biological repairs should be—realisti-
cally—considered ‘temporary’ reinforcement barriers, act-
ing as a mean of delaying inevitable recurrence of a hernia 
in complex fields.
A recent review [120] (EL 3) compared recurrence 
rates obtained by different biological meshes, suggesting 
 Permacol® had the lowest failure rate and the longest time 
to failure, particularly in contaminated fields. The authors 
of this review included Shaikh study on 20 patients with 
acute and chronic abdominal wall defects and meshes 
placed in potentially contaminated fields (15% recurrence 
at 18-month follow-up), Catena study on seven patients with 
incisional hernias in contaminated fields (no recurrence at 
11.2 months) and Parker study including also five patients 
with contaminated wounds (class II–II–IV) and one recur-
rence at 13 months of follow-up.
Studies with longer follow-up are awaited to assess the 
durability over time of biological prosthetics, given their 
biodegradable nature. Although biological meshes represent 
one of the most promising alternatives to a two-stage repair 
in compromised abdominal fields, still a more convincing 
evidence of their long-term results is necessary to overcome 
resistance to their use, especially in Europe, due to their 
high cost.
10. Complications and their treatment after biological mesh 
implant.
Infectious events are the most relevant complications. 
Controversial findings of surgical site infection rate do not 
allow identifying clear differences between cross-linked 
and not cross-linked mesh. The surgical site occurrences 
are usually managed non-operatively or require minimal 
operative treatment. Mesh removal is uncommon (WEAK 
RECOMMENDATION).
Surgical complications after abdominal wall repair with 
biological mesh are mainly related to wound events and 
they can define as surgical site occurrence (SSO). A recent 
systematic review, including 1.152 patients, documented an 
SSO rate of 46.3% [88] (EL 2). The comparison of morbidity 
between wound classes regarding infection and total surgical 
morbidity showed that both were dependent on wound class 
[88] (EL 2). The infection and total surgical morbidity were 
significantly higher in the contaminated/dirty group than in 
the clean/clean-contaminated group [88] (EL 2). The SSO 
according to the ventral hernia working group’s (VHWG) 
grading system could not be evaluated accurately because 
of inadequate study details of several reports [86] (EL 2). 
However, an author found a lower rate of complications in 
grade 3 patients, when biologic is compared with synthetic 
mesh [144] (EL 3). A recent metanalysis reported no signifi-
cant difference in wound complication rates in ventral hernia 
repair with human-derived biologic grafts compared with 
porcine biologic mesh [145] (EL 2) but data in the literature 
are still controversial. Another systematic review, includ-
ing 60 studies with a total of 1.241 patients, reported an 
SSO rate of 52.8%, and combining mesh product by a source 
the rate was: human dermis 48.3%, porcine small intestinal 
submucosa 82.6%, xenogenic dermis 50.7%, xenogenic peri-
cardium 6.3% [86] (EL 2). Additionally, another Author ana-
lyzed SSO divided by biologic graft with regard to infection, 
seroma formation and total surgical morbidity and human 
dermis and porcine intestine had a higher rate of infectious 
than porcine dermis, as well seroma formation rate: total 
surgical morbidity was lower with porcine dermis comparing 
with human dermis and porcine intestine [88] (EL 2). Fur-
thermore analyzing and comparing data of all porcine cross-
linked mesh with porcine non-cross-linked, it was shown 
that infection rates were 9.1% for porcine cross-linked and 
18% for non-cross-linked [86] (EL 2). Comorbidities such 
as hypertension, diabetes mellitus coronary artery disease, 
ASA score, are not in correlation with wound complications, 
while age > 60 years, BMI, long surgical time, use of large 
or more than one sheet of prothesis were associated with an 
SSO [146–148] (EL 2). Surgical site occurrence was divided 
into infectious and non-infectious complications. Infectious 
complications include purulence, cellulitis, positive culture, 
chronic wound infection, abscess, enterocutaneous fistula 
and mesh infectious, whereas edema, seroma, hematoma, 
wound dehiscence, skin necrosis, bleeding and fluid collec-
tions were considered non-infectious [86, 145] (EL 2–3). In 
a metanalysis comparing biologic versus non-biologic mesh, 
the former demonstrated a lower rate of infectious wound 
complications and an equivalent rate of non-infectious 
wound complications when compared with non-biologic 
mesh [86] (EL 3). In the literature, infection rates range from 
5.4 to 57.1% when a biologic mesh is used for ventral hernia 
repair, however, the wound complication rate of 10.9% in 
this metanalysis was lower than the 36.5% of the mean com-
plication rate for synthetic mesh [86] (EL 3). A systematic 
review reported a wound infectious rate of 15.9%, but the 
majority of infections were superficial [88] (EL 2) and other 
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infectious complications were intrabdominal abscesses in 
2.4% and miscellaneous in 2.7%. The postoperative course 
was complicated by an enterocutaneous fistula in 6.5% of 
cases, of this 56% was related to fistula takedown performed 
concomitantly with the hernia repair, 10.4% after bowel sur-
gery and 12.6% in patients with open wounds or after simple 
ventral hernia repair [88] (EL 2). A prospective controlled 
study (RICH study) revealed as in 67% of patients a minimal 
treatment was required to treat the postoperative infections 
[91] (EL 1). They can manage successfully by incision and 
drainage with antibiotic therapy. In front of this, a major-
ity of the patients were able to maintain the reconstruction 
without the need for explantation [91]. Systematic reviews 
confirm the need for removing the grafts in only 4.9% and 
2% of patients [86, 88] (EL 2–3). Whereas after synthetic 
mesh repair, mesh removal is mandatory when infection 
develops. A retrospective cohort study showed the hernia 
grade as the only independent factor associated with mesh 
explantation [149] (EL 2). Patients with a hernia grade of 4 
had 15-fold increased risk of mesh explantation when com-
pared to patients with hernia grade 1 and the rate of mesh 
explantation for grade 1 and 2 hernias were similar between 
biologic and synthetic mesh [149] (EL 2).
Related to non-infectious complications, an author 
reported a seroma formation of 14.2% [88], of these five 
cases of explantation, were documented after significant 
seroma formation in a report of repair with porcine intes-
tine mesh [150]. Haematomas incidence rate was reported 
3% on 354 patients [88] (EL 2). In another review, seroma/
hematoma was the second most common complication 
reported and occurred in 12% of patients [86] (EL 2). Most 
seroma resolved either spontaneously or after percutane-
ous aspiration requiring a bedside or outpatient interven-
tion (21.4% of patients) and in few cases (14.2%) a surgical 
intervention [86] (EL 2). Other postoperative wound-related 
complications were skin necrosis/breakdown (16.9%) and 
graft rejection/degradation (2.5%) in a series, while another 
reported superficial dehiscence 3.8%, skin necrosis 0.9%, 
mesh disintegration 0.5% and flap necrosis 0.3% [86, 88] 
(EL 2). Deep wound dehiscence necessitating operative 
intervention was documented in 8.6% of 191 patients [88] 
(EL 2). In cases of skin necrosis involving deep tissue, the 
mesh can be exposed. Operative debridement of the wound 
is necessary to determine the extent of necrosis and choosing 
the right dressing will ensure the hydration to the biologic 
graft. Option for dressing includes hydrating gels, enzymatic 
debridement agents, micro-debridement dressing and VAC 
therapy [151] (EL 4). Mortality after ventral hernia repair 
with biologic mesh is usually unrelated to biologic prothesis 
(e.g., multiple organ failure, congestive heart failure, and 
disseminated intravascular coagulation). Systematic reviews 
reported an overall mortality rate of about 4% and a 30 days 
mortality of 2.3% [86, 88] (EL 2).
11. The use of negative pressure wound therapy (NPWT) in 
complex abdominal wall repair’s SSO (Surgical Site Occur-
rence) with synthetic meshes and biological implants.
NPWT can be safely used both with synthetic and bio-
logic infected meshes (WEAK RECOMMENDATION).
NPWT is useful because promotes granulation tissue 
formation and tissue ingrowth over the synthetic mesh 
(STRONG RECOMMENDATION).
NPWT could reduce hospital-stay with a decreased rate 
of complications (WEAK RECOMMENDATION).
Negative pressure wound therapy (NPWT) has shown 
many promising results in different types of wounds. The 
evidence for the effects of NPWT in reducing SSI and wound 
dehiscence remains unclear, as does the effect of NPWT on 
time to complete healing [46]. The use of NPWT in the case 
of an open abdomen or split-thickness skin graft was well 
established in practice and the clinical guidelines have been 
readily available [152, 153]. Several therapeutic strategies 
have been advocated in the past to treat deep mesh infec-
tions, ranging from complete excision of the mesh, local 
excision of some parts of the mesh to local drainage with 
concomitant intravenous antibiotics [154–156]. A possible 
alternative to the above methods is the NPWT, which is a 
non-invasive and dynamic way to obtain mesh coverage and 
adequate wound closure [157–159] (EL 2). NPWT can be 
used in the treatment and salvage of infected meshes after 
hernia repair [159–161] (EL 2). Best results can be achieved 
in the case of infection of deep mesh with a large pore size 
(2–5 mm) when compared to small pore size meshes. The 
wider pore size favors tissue ingrowth, leading to better 
incorporation and diminishing the mesh surface area [162]. 
The difference between polyester and polypropylene is still 
under debate [163–165]. The affinity of different meshes 
to bacteria has also been studied, and it is established that 
microporous and multifilament meshes do have a higher 
affinity for bacterial contamination [165, 166] (EL 2).
Biologic mesh performs like a scaffold for the granula-
tion tissue that is stimulated by the negative pressure. The 
mesh must be covered by Vaseline gauze or polyvinyl alco-
hol foam (interface dress) to prevent adherence with the 
implant. NPWT should start at − 75 mmHg pressure, then 
progressively increase at − 125 mmHg continue pressure. 
Sometimes the implant can break or flake and early granula-
tion can be observed inside the mesh perforation [166–168]. 
NPWT promotes granulation tissue formation through the 
mesh, that occurs 1–7 weeks after its implant [158] (EL 
2).The formation of granulation tissue allows the application 
of a skin graft on the biologic material [167] (EL 4).
Future multi-site, prospective, controlled studies would 
provide a strong evidence base from which treatment deci-
sions could be made in the management of these challenging 
and costly cases. Additionally, cost–benefit studies examin-
ing the use of newer adjunctive technologies, such as V.A.C. 
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 Instill® Wound Therapy and GranuFoam Silver (KCI Licens-
ing, Inc., San Antonio, TX) dressing, earlier in the treat-
ment course, are needed in addition to the use of alternative 
biologic meshes of both human and porcine matrices [158, 
159, 166, 167] (EL 3–4).
12. The recurrence after biological mesh implant.
Hernia recurrence after abdominal wall repair with bio-
logical mesh is comparable to repair with non-biologic 
mesh. No significative differences in recurrence rate are 
found among several types of biological meshes (WEAK 
RECOMMENDATION).
There is an evident correlation between hernia recurrence 
and postoperative infection as well as repair performed in 
contaminated field and in high-risk patients. The use of bio-
logical mesh in bridge technique results in a high recur-
rence rate, thus the fascial closure with or without compo-
nent separation technique should be achieved when possible 
(STRONG RECOMMENDATION).
The prosthetic mesh can be used safely in recur-
rent hernias, without biological mesh removal (WEAK 
RECOMMENDATION).
The most frequently described major complication after 
ventral hernia repair with biological mesh is recurrence. The 
reported frequency of recurrence varied from 0 to 100% with 
an overall weighted recurrence rate of 15.2% [86] (EL 3). 
Hernia recurrence is defined as any kind of repair failure, 
including postoperative hernia, laxity, bulge, eventration, 
or diastasis [145] (EL 2) and is based on clinical exami-
nation findings; only those patients with suspected hernia 
recurrence usually undergo confirmatory imaging studies 
and probably if all patients were imaged, the incidence of 
recurrence would likely be higher [169]. In assessing recur-
rence rates, the duration of follow-up is a key issue for two 
reasons: short-term follow-up can underestimate the recur-
rence rate and the results of two studies cannot be com-
pared unless the follow-up duration is similar. Short term 
recurrence are likely to be due to either technical issue, as 
mechanical failures perhaps resulting from an inequality 
between high tension and force placed on the mesh, and 
very high-risk patients (smoking, obesity, pulmonary dis-
ease); whereas late recurrences suffered from prolonged 
wound healing and infectious complications [120, 169] (EL 
2–3). Thus, recurrence rate increase among the length of 
follow-up, as in a prospective study with non-cross-linked 
porcine dermal mesh the recurrence rate is 19% at 12 months 
and 28% at 24 months [91] (EL 1). A longer follow-up, like 
5 years, would answer if the biological mesh is reliable as 
definitive repair in high-risk patients [170] (EL 3). In a meta-
nalysis, the average recurrence rate for ventral hernia repair 
across all the studies was 17.1% and was not significantly 
different between biologic mesh (18.6%) and non-biologic 
mesh (15.7%) [145] (EL 2) and there was no significative 
difference in recurrence rates for human-derived and por-
cine-derived biologic grafts [145] (EL 2). The risk factors 
influencing recurrence are patient factors (increased intra-
abdominal pressure, diminished tissue integrity) and tech-
nical factors (infection, lateral mesh distraction, missed 
hernia) [69] (El 3). It is estimated that more than 75% of 
all recurrence is due to infection and inadequate repair mate-
rial fixation and/or overlap [69] (EL 3). However, wound 
infection appears to significantly increase the risk for hernia 
recurrence [69] (EL 3) [169] (EL 2). Furthermore, a system-
atic review found that across all studies, hernia recurrence 
correlated with the presence of postoperative infection [88] 
(EL 2). There were significantly fewer recurrences in clean 
fields compared with contaminated or infected fields and 
the complex/high-risk patients, even at short term follow-
up [88, 120] (EL 2). Whereas one study reported an overall 
recurrence rate of 30% in contaminated fields [171] (EL 
3), some Authors found a strong correlation between the 
wound class and the recurrence rate, with a 39% rate in dirty 
fields against 4.5% in clean fields [172] (EL 3). Whether 
mesh should be used as an onlay, sublay or bridge prosthesis 
remains a source of debate within the surgical literature. 
In a metanalysis biologic mesh combined with component 
separation technique (CST) reported a recurrence rate of 
18.5% that is higher than the 11.4% recurrence rate of CST 
with non-biologic mesh [145] (EL 1). If the fascial closure, 
with or without CST, is achieved the recurrence rate is lower 
than no fascial closure, as in bridge technique, 23% vs 44% 
in 24 months of follow-up [91] (EL 1). The largest published 
experience with human dermal mesh used as bridge demon-
strates recurrence in 20.2% of cases [173] (EL 3). A retro-
spective study on porcine dermal cross-linked mesh reveals 
a recurrence rate at 5 years follow-up, with reinforcement 
technique by onlay or sublay placement, of 20 and 53%, 
respectively, and an 80% recurrence when bridge technique 
was used [170] (EL 3). Some authors report problems with 
bulging and diastasis at the repair site when human der-
mis is used, probably due to stretching of the mesh [140, 
174] (EL 3). In a retrospective study comparing bridged and 
reinforced technique the only predictive factor for hernia 
recurrence was the use of the bridging technique [136] (EL 
3). When recurrence occurs, it can be successfully repaired 
with prosthetic mesh even in minimally or potentially con-
taminated field without explantation of previously biological 
mesh [175] (EL 4).
13. Nutritional and antimicrobial support treatment.
Early enteral nutrition in the open abdomen should be 
considered in all patients with a viable gastrointestinal tract 
(STRONG RECOMMENDATION).
An antibiotic perioperative prophylaxis is essential in 
all cases. In the case of gross contamination, a therapy 
of broad-spectrum antibiotics should be continued for 
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4–7 days or more according to clinical conditions (WEAK 
RECOMMENDATION).
The advantage of early Enteral Nutrition (EN), like reduc-
tion in septic complications, in the patient with a severe 
injury, is well documented. Its application in those patients 
with an open abdomen has yet to be defined. One study 
reports increased fascial closure rates with the initiation of 
EN before day 4 after injury [176] (EL 3) Another study sug-
gests a reduced incidence of ventilator-associated pneumo-
nia with early EN but shows no impact of EN on abdominal 
closure rates [177] (EL 3). In Patients with an intact gas-
trointestinal tract, Moore et al. have shown it is safe to feed 
the patient with an open abdomen. These benefits appear to 
decrease the time for abdominal fascial closure, decrease 
complication rates, decreased mortality. Although EN for 
patients with bowel injuries does not seem to alter fascial 
closure rates, complications, or mortality [178] (EL 3). The 
open abdomen does not warrant any additional period of 
antibiotic coverage. In most cases, perioperative antibiotic 
treatment is all that is required [179] (EL 3). There is no 
difference in the complication rate between prophylactic 
and prolonged antibiotic use [180] (EL 3). For patients with 
complicated intra-abdominal infection, no unique antibiotic 
strategies are recommended. Therapy should be limited to 
4–7 days, as was recommended in the Surgical Infection 
Society guidelines for complicated intra-abdominal infec-
tions [181] (EL 2).
Discussion
Although in elective surgery the term “complex abdomen” 
is often used as a synonym for “complex abdominal wall 
hernia”, where the main problem is to face a technically 
challenging and time-consuming hernias, in emergency situ-
ations to close and how the abdominal wall might represent, 
in particular and demanding situations, a surgical nightmare 
to solve by surgeons. As it is intuitive and despite the prob-
lem’s frequency, there is no an easy and unique solution for a 
complex abdomen. The treatment as to be often tailored and 
individualized, bringing in mind two priorities.
The first one is to control or, if possible, to prevent “the 
causative source” and its related complications. In the first 
situation, decompressive laparostomy should be considered 
in a case of abdominal compartment syndrome in patients 
with critical conditions or after the failure of a medical treat-
ment or less invasive methods. In the second one, beyond 
different mechanism, patients with surgical emergency dis-
eases might reach the same pathophysiological end point 
of trauma patients where a preventive “open abdomen” 
might be indicated. A temporary abdominal closure might 
be achieved with different techniques: in the case of a non-
infected field, the Wittmann patch, and the NPWT had the 
best outcome followed by meshes (to prevent also the lateral 
fascial retraction). In the case of an infected field, NPWT 
techniques seem to be the preferred in both the situations, 
the main goals to be achieved are the definitive closure, as 
soon as possible, of the abdomen. Within 9 days has been 
reported to be the ideal time.
The second priority is to create optimal both general as 
local conditions for healing: the right antimicrobial manage-
ment, feeding—preferably by the enteral route, and man-
aging correctly the open abdomen wall. No doubt that to 
minimize hernia recurrences, the use of a mesh appears to 
be—if and when possible—the gold standard. There is a lot 
of enthusiasm about biological meshes. But the actual evi-
dence supports their use only in contaminated or potentially 
contaminated fields but above all, to reduce the higher rate 
of recurrences, the wall anatomy and function should be 
restored in the midline, with or without component separa-
tion technique. On the other site has not to be neglected that 
the use of monofilament and macroporous non-absorbable 
meshes, in extraperitoneal position, in the setting of the 
complex abdomen with contamination, seems to have a cost 
effective role too.
The treatment of a patient with a complex abdomen 
requires not only a deep understanding of the treatment 
options and consciousness of all the possible morbidities 
but the involvement of different specialties, keeping in mind 
that the key issues are timing and coordination.
The idea of this consensus conference was mainly to try 
to bring order in the so copious, but not always so “evident” 
literature utilizing and exchanging the expertise of different 
specialists.
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